A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe, John A. Blessing, George Olt, Nader Husseinzadah, Samuel S. Lentz, Koenraad De Geest, Fidel A. Valea

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

NSC 366140
Oncology
Cervix Uteri
Squamous Cell Carcinoma
Neutropenia
Chemotherapy
Toxicity
Appointments and Schedules
Epithelial Cells
Drug Therapy

Keywords

  • Cervical cancer
  • Pyrazoloacridine
  • PZA

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix : A gynecologic oncology group study. / Plaxe, Steven C.; Blessing, John A.; Olt, George; Husseinzadah, Nader; Lentz, Samuel S.; De Geest, Koenraad; Valea, Fidel A.

In: Cancer Chemotherapy and Pharmacology, Vol. 50, No. 2, 2002, p. 151-154.

Research output: Contribution to journalArticle

Plaxe, Steven C. ; Blessing, John A. ; Olt, George ; Husseinzadah, Nader ; Lentz, Samuel S. ; De Geest, Koenraad ; Valea, Fidel A. / A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix : A gynecologic oncology group study. In: Cancer Chemotherapy and Pharmacology. 2002 ; Vol. 50, No. 2. pp. 151-154.
@article{d8f366a0ba9744119f9e128f422fb1a1,
title = "A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study",
abstract = "Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2{\%}) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.",
keywords = "Cervical cancer, Pyrazoloacridine, PZA",
author = "Plaxe, {Steven C.} and Blessing, {John A.} and George Olt and Nader Husseinzadah and Lentz, {Samuel S.} and {De Geest}, Koenraad and Valea, {Fidel A.}",
year = "2002",
doi = "10.1007/s00280-002-0470-2",
language = "English (US)",
volume = "50",
pages = "151--154",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix

T2 - A gynecologic oncology group study

AU - Plaxe, Steven C.

AU - Blessing, John A.

AU - Olt, George

AU - Husseinzadah, Nader

AU - Lentz, Samuel S.

AU - De Geest, Koenraad

AU - Valea, Fidel A.

PY - 2002

Y1 - 2002

N2 - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

AB - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

KW - Cervical cancer

KW - Pyrazoloacridine

KW - PZA

UR - http://www.scopus.com/inward/record.url?scp=0036353160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036353160&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0470-2

DO - 10.1007/s00280-002-0470-2

M3 - Article

C2 - 12172981

AN - SCOPUS:0036353160

VL - 50

SP - 151

EP - 154

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -